141 related articles for article (PubMed ID: 19296137)
21. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
Kehl SC; Dowzicky MJ
J Clin Microbiol; 2015 Apr; 53(4):1286-93. PubMed ID: 25653413
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
Tärnberg M; Nilsson LE; Dowzicky MJ
Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
Zhang YY; Zhou L; Zhu DM; Wu PC; Hu FP; Wu WH; Wang F
Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.
Liu CY; Lu CL; Huang YT; Liao CH; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1437-42. PubMed ID: 19763644
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
28. [In vitro activity of tigecycline on 760 bacterial strains isolated in the hospital university of Angers--2006-2009 TEST study].
Bris C; Auger G; Kowalczyk F; Eveillard M; Joly-Guillou ML; Kempf M
Pathol Biol (Paris); 2012 Dec; 60(6):336-9. PubMed ID: 22197193
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
31. A review of tigecycline--the first glycylcycline.
Peterson LR
Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.
Petersen PJ; Ruzin A; Tuckman M; Jones CH
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):407-18. PubMed ID: 20226331
[TBL] [Abstract][Full Text] [Related]
33. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
[TBL] [Abstract][Full Text] [Related]
35. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan.
Cheng NC; Hsueh PR; Liu YC; Shyr JM; Huang WK; Teng LJ; Liu CY
Microb Drug Resist; 2005; 11(4):330-41. PubMed ID: 16359192
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Nagy E; Dowzicky MJ
Scand J Infect Dis; 2010; 42(1):33-8. PubMed ID: 19883155
[TBL] [Abstract][Full Text] [Related]
37. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).
Farrell DJ; Turnidge JD; Bell J; Sader HS; Jones RN
J Infect; 2010 Jun; 60(6):440-51. PubMed ID: 20361999
[TBL] [Abstract][Full Text] [Related]
38. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
Hope R; Mushtaq S; James D; Pllana T; Warner M; Livermore DM;
J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
[TBL] [Abstract][Full Text] [Related]
39. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Alvarez J; Picazo JJ;
Antimicrob Agents Chemother; 2002 Mar; 46(3):892-5. PubMed ID: 11850282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
